Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Elevai Labs, Inc. Common Stock

Healthcare US ELAB

1.41USD
0.00(0%)

Last update at 2026-06-10T20:29:00Z

Day Range

1.341.55
LowHigh

52 Week Range

1.62268.79
LowHigh

Fundamentals

  • Previous Close 1.41
  • Market Cap14.64M
  • Volume6827262
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-7.02671M
  • Revenue TTM0.59M
  • Revenue Per Share TTM28.99
  • Gross Profit TTM -1.03234M
  • Diluted EPS TTM-382.61

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2023-09-30 2022-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2023-09-30 2022-12-31
Income before tax -7.74977M -4.01671M -4.30152M -4.30152M -1.80027M
Minority interest - - - - -
Net income -7.70814M -6.24574M -4.30152M -4.30152M -1.80027M
Selling general administrative 1.42M 0.56M 3.37M 4.03M 1.73M
Selling and marketing expenses 0.20M 0.29M 0.66M - -
Gross profit 0.07M 1.80M 1.13M 1.13M 0.45M
Reconciled depreciation 0.10M 0.01M 0.01M 0.01M 0.00651M
Ebit -7.37671M -3.28152M -4.28199M - -
Ebitda -7.26621M -3.19841M -4.27034M - -
Depreciation and amortization 0.11M 0.08M 0.01M - -
Non operating income net other - - - - -
Operating income -7.37671M -1.86657M -3.76008M -3.76008M -1.78829M
Other operating expenses 7.97M 4.33M 5.47M - -
Interest expense 0.55M 0.74M 0.02M 0.02M 0.00263M
Tax provision 0.03M 0.00000M - - -
Interest income 0.12M 0.01M 0.00556M 0.00556M 0.00770M
Net interest income -0.42910M -0.72231M -0.01396M -0.01396M 0.00507M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.03M - 0.00000M - -
Total revenue 0.59M 2.47M 1.71M 1.71M 0.77M
Total operating expenses 7.45M 3.66M 4.89M 5.47M 2.55M
Cost of revenue 0.52M 0.67M 0.58M 0.58M 0.32M
Total other income expense net -0.37306M -2.14971M -0.54144M -0.52748M -0.01705M
Discontinued operations - - - - -
Net income from continuing ops -7.78074M -4.01671M -4.30152M -4.30152M -1.80027M
Net income applicable to common shares - - - - -
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2023-09-30 2022-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2023-09-30 2022-12-31
Total assets 12.87M 8.99M 5.19M 5.19M 1.89M
Intangible assets 2.89M 2.80M - - -
Earning assets - - - - -
Other current assets 1.03M 2.06M 1.06M - -
Total liab 5.03M 2.33M 1.36M 1.36M 0.76M
Total stockholder equity 7.84M 6.66M 3.83M 3.83M 1.13M
Deferred long term liab - - - - -
Other current liab 2.36M 1.32M 0.52M 0.37M 0.07M
Common stock 0.00001M 0.00004M 0.00173M - -
Capital stock 0.00064M 0.00004M 0.00173M 0.00173M 0.00153M
Retained earnings -21.01744M -13.26963M -7.02389M -7.02389M -2.72237M
Other liab - - - - -
Good will 0.98M 0.00000M - - -
Other assets - - 0.00000M - -
Cash 5.40M 3.98M 3.33M 3.33M 1.15M
Cash and equivalents - - - - -
Total current liabilities 3.94M 1.80M 1.30M 1.30M 0.59M
Current deferred revenue - - 0.04M - -
Net debt -2.75738M -3.98445M -3.11636M - -
Short term debt 1.59M - 0.14M - -
Short long term debt 1.34M - - - -
Short long term debt total 2.64M - 0.21M - -
Other stockholder equity 28.86M 19.93M 10.85M - -
Property plant equipment - - - - -
Total current assets 6.87M 6.05M 4.92M 4.92M 1.55M
Long term investments 0.00000M 0.14M 0.00000M - -
Net tangible assets - - - - -
Short term investments 0.57M 0.00000M - - -
Net receivables 0.34M 0.00528M 0.04M 0.03M 0.00418M
Long term debt 0.09M - - - -
Inventory 0.10M 0.00104M 0.50M 0.50M 0.23M
Accounts payable 0.70M 0.48M 0.60M 0.60M 0.22M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.00234M -0.00034M 0.00020M - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 0.14M 0.01M - -
Deferred long term asset charges - - - - -
Non current assets total 6.00M 2.94M 0.27M 0.27M 0.34M
Capital lease obligations 1.22M 0.00000M 0.21M 0.21M 0.28M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2023-09-30 2022-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2023-09-30 2022-12-31
Investments -0.02684M -0.61056M -0.01119M -0.01119M -0.03203M
Change to liabilities - - - - -
Total cashflows from investing activities -2.76515M -0.61056M -0.01119M - -
Net borrowings 0.00000M -0.23556M 0.00000M - -
Total cash from financing activities 10.12M 6.76M 6.74M 6.74M 2.36M
Change to operating activities - - - - -
Net income -7.74781M -6.24574M -4.30152M -4.30152M -1.80027M
Change in cash 1.42M 0.66M 2.17M 2.17M 0.74M
Begin period cash flow 3.98M 3.33M 1.15M 1.15M 0.41M
End period cash flow 5.40M 3.98M 3.33M 3.33M 1.15M
Total cash from operating activities -5.93388M -5.48698M -4.55681M -4.55681M -1.58588M
Issuance of capital stock 2.92M 6.99M 7.46M 7.46M 2.15M
Depreciation 0.10M 0.01M 0.01M 0.01M 0.00651M
Other cashflows from investing activities -0.68947M -0.46232M - - -
Dividends paid - - - - -
Change to inventory 0.15M -0.40330M -0.26552M -0.26552M -0.06933M
Change to account receivables -0.10059M -0.01297M -0.02322M - -
Sale purchase of stock -0.00018M 0.00000M - - -
Other cashflows from financing activities 3.99M 6.76M -0.72469M - -
Change to netincome - - - - -
Capital expenditures 0.45M 0.00916M 0.01M 0.01M 0.04M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.59M 0.25M -0.82319M -0.82319M 0.01M
Stock based compensation -0.01916M 0.10M 0.49M 0.49M 0.17M
Other non cash items 1.12M 0.40M 0.07M -0.00276M 0.00928M
Free cash flow -6.38214M -5.48698M -4.56800M -4.56800M -1.62140M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x)
ELAB
Elevai Labs, Inc. Common Stock		 - -% 1.41 - - 24.81 0.82 5.26
NVO
Novo Nordisk A/S		 0.62 1.47% 42.81 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.70 4.09% 43.30 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -10.06 2.26% 435.71 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -14.53 2.36% 601.65 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of cutting-edge aesthetic medicines and therapeutic products. The company's lead product includes EL-22, a first-in-class engineered probiotic approach to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. It is also involved in the medical scientific research and development activities, as well as operates investment firms. The company was formerly known as Elevai Labs, Inc. and changed its name to PMGC Holdings Inc. in December 2024. PMGC Holdings Inc. was incorporated in 2020 and is based in Newport Beach, California.

Elevai Labs, Inc. Common Stock

120 Newport Center Drive, Newport Beach, CA, United States, 92660

Key Executives

Name Title Year Born
Dr. Jordan R. Plews Ph.D. Co-Founder, President, CEO & Director 1984
Ms. Brenda Buechler Chief Marketing Officer 1971
Mr. Christoph Kraneiss Chief Commercial Officer 1972
Dr. Hatem Abou-Sayed F.A.C.S., FACS, M.B.A., M.D., MBA Co-Founder, Chief Medical Officer & Director 1972
Mr. Graydon Bensler C.F.A. CFO, Secretary & Director 1992
Mr. Graydon Bensler C.F.A. CEO, CFO, Secretary & Director 1992

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions